using our proprietary platform technology, gt biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute myeloid leukemia, myeloid dysplastic syndrome, and multiple solid tumors by leveraging our proprietary nk cell engager (trike) platform technology. (nasdaq: gtbp)
![GT Biopharma logo](/files/LOGO/109657-GTBP.png)
Company profile
Ticker
GTBP
Exchange
Website
CEO
Anthony Cataldo
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
OXIS INTERNATIONAL INC
SEC CIK
Corporate docs
IRS number
941620407
GTBP stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
17 Jun 24
8-K
Departure of Directors or Certain Officers
7 Jun 24
424B5
Prospectus supplement for primary offering
23 May 24
8-K
GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
23 May 24
10-Q
2024 Q1
Quarterly report
15 May 24
8-K
Entry into a Material Definitive Agreement
30 Apr 24
ARS
2023 FY
Annual report to shareholders
29 Apr 24
DEFA14A
Additional proxy soliciting materials
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
10-K
2023 FY
Annual report
26 Mar 24
Transcripts
Latest ownership filings
3
ALAN LOUIS URBAN
13 Jun 24
SC 13G/A
BRISTOL INVESTMENT FUND LTD
23 May 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G
CYTOVANCE BIOLOGICS INC
19 Sep 23
4
Michael Martin Breen
15 Aug 23
4
Manu Ohri
15 Aug 23
4
CHARLES J CASAMENTO
21 Jun 23
3
CHARLES J CASAMENTO
4 May 23
4
Michael Martin Breen
11 Apr 23
4
Manu Ohri
10 Apr 23
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.95 mm | 1.95 mm | 1.95 mm | 1.95 mm | 1.95 mm | 1.95 mm |
Cash burn (monthly) | (no burn) | 7.92 k | 1.03 mm | 1.08 mm | 1.39 mm | 842.42 k |
Cash used (since last report) | n/a | 20.89 k | 2.72 mm | 2.86 mm | 3.66 mm | 2.22 mm |
Cash remaining | n/a | 1.93 mm | -769.02 k | -909.32 k | -1.71 mm | -273.11 k |
Runway (months of cash) | n/a | 243.7 | -0.7 | -0.8 | -1.2 | -0.3 |
Institutional ownership, Q4 2023
13F holders | Current |
---|---|
Total holders | 4 |
Opened positions | 0 |
Closed positions | 31 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 4.30 mm |
Total shares | 3.03 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Cytovance Biologics | 2.76 mm | $860.00 k |
Alpha Capital Anstalt | 265.23 k | $809.00 k |
Welch | 10.00 k | $2.55 mm |
Blue Bell Private Wealth Management | 300.00 | $77.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Aug 23 | Michael Martin Breen | Common Stock | Grant | Acquire A | No | No | 0.287 | 200,000 | 57.40 k | 856,218 |
11 Aug 23 | Manu Ohri | Common Stock | Other | Acquire J | Yes | No | 0.287 | 200,000 | 57.40 k | 300,000 |
11 Aug 23 | Manu Ohri | Common Stock | Other | Dispose J | No | No | 0.287 | 200,000 | 57.40 k | 0 |
11 Aug 23 | Manu Ohri | Common Stock | Grant | Acquire A | No | No | 0.287 | 200,000 | 57.40 k | 200,000 |
16 Jun 23 | Casamento Charles J | Option to purchase Common Stock Common Stock | Grant | Acquire A | No | No | 0.35 | 500,000 | 175.00 k | 500,000 |
News
12 Health Care Stocks Moving In Wednesday's Intraday Session
22 May 24
12 Health Care Stocks Moving In Tuesday's Intraday Session
21 May 24
What's Going On With GT Biopharma Stock Tuesday?
21 May 24
12 Health Care Stocks Moving In Monday's After-Market Session
20 May 24
What's Going On With GT Biopharma Stock?
20 May 24